Literature DB >> 34097494

Antibiotic Cycling Reverts Extensive Drug Resistance in Burkholderia multivorans.

L G Kavanaugh1,2, S K Harrison2, J N Flanagan2, T R Steck2.   

Abstract

Antibiotic collateral sensitivity, in which acquired resistance to one drug leads to decreased resistance to a different drug, occurs in Burkholderia multivorans. Here, we observed that treatment of extensively drug-resistant variants evolved from a cystic fibrosis (CF) sputum sample isolate with either meropenem or sulfamethoxazole-trimethoprim, depending on past resistance phenotypes, resulted in increased sensitivity to five different classes of antibiotics. We further identified mutations, including putative resistance-nodulation-division efflux pump regulators and uncharacterized pumps, that may be involved in this phenotype in B. multivorans.

Entities:  

Keywords:  Burkholderia; XDR; antibiotic resistance; collateral sensitivity; combination antibiotic; sequential therapy

Mesh:

Substances:

Year:  2021        PMID: 34097494      PMCID: PMC8284468          DOI: 10.1128/AAC.00611-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Julian A Gatta; Nozomi Ohuchi; Robert A Bonomo; Michiyoshi Nukaga
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

2.  Boosting Secretion of Extracellular Protein by Escherichia coli via Cell Wall Perturbation.

Authors:  Haiquan Yang; Xiao Lu; Jinyuan Hu; Yuan Chen; Wei Shen; Long Liu
Journal:  Appl Environ Microbiol       Date:  2018-10-01       Impact factor: 4.792

Review 3.  Lung transplantation in cystic fibrosis patients with difficult to treat lung infections.

Authors:  Lieven Dupont
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

4.  Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a cystic fibrosis patient.

Authors:  Joshua R Stokell; Raad Z Gharaibeh; Todd R Steck
Journal:  J Cyst Fibros       Date:  2013-03-09       Impact factor: 5.482

5.  Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).

Authors:  Bindu M Nair; K-John Cheung; Adam Griffith; Jane L Burns
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

6.  Efflux pump-mediated drug resistance in Burkholderia.

Authors:  Nicole L Podnecky; Katherine A Rhodes; Herbert P Schweizer
Journal:  Front Microbiol       Date:  2015-04-14       Impact factor: 5.640

7.  Drug-Driven Phenotypic Convergence Supports Rational Treatment Strategies of Chronic Infections.

Authors:  Lejla Imamovic; Mostafa Mostafa Hashim Ellabaan; Ana Manuel Dantas Machado; Linda Citterio; Tune Wulff; Soren Molin; Helle Krogh Johansen; Morten Otto Alexander Sommer
Journal:  Cell       Date:  2018-01-04       Impact factor: 41.582

8.  Mechanisms and therapeutic potential of collateral sensitivity to antibiotics.

Authors:  Roderich Roemhild; Dan I Andersson
Journal:  PLoS Pathog       Date:  2021-01-14       Impact factor: 6.823

9.  DELLY: structural variant discovery by integrated paired-end and split-read analysis.

Authors:  Tobias Rausch; Thomas Zichner; Andreas Schlattl; Adrian M Stütz; Vladimir Benes; Jan O Korbel
Journal:  Bioinformatics       Date:  2012-09-15       Impact factor: 6.937

10.  LUMPY: a probabilistic framework for structural variant discovery.

Authors:  Ryan M Layer; Colby Chiang; Aaron R Quinlan; Ira M Hall
Journal:  Genome Biol       Date:  2014-06-26       Impact factor: 13.583

View more
  1 in total

1.  Conservation of Resistance-Nodulation-Cell Division Efflux Pump-Mediated Antibiotic Resistance in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Species.

Authors:  Nawarat Somprasong; Jinhee Yi; Carina M Hall; Jessica R Webb; Jason W Sahl; David M Wagner; Paul Keim; Bart J Currie; Herbert P Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.